Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20310 | 0.84 | F2 (0.50) | F2PRSS1PRSS2PRSS3MEN1 | |
| Trifluoroacetic Acid SCHEMBL31389570 | 0.83 | MAPT (0.41) | F2PRSS1PRSS2PRSS3MEN1 | |
| Hydrochloric Acid SCHEMBL28479231 | 0.82 | F2 (0.49) | F2PRSS1PRSS2PRSS3MEN1 | |
| Methylene Chloride SCHEMBL23923198 | 0.78 | F2 (0.45) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL301212 | 0.75 | F2 (0.47) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL20626670 | 0.73 | F2 (0.44) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL6121500 | 0.73 | CA1 (0.48) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL8316156 | 0.71 | MAPT (0.41) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL9953282 | 0.70 | F2 (0.50) | F2PRSS1PRSS2PRSS3MEN1 | |
| SCHEMBL383918 | 0.70 | NR3C2 (0.42) | F2PRSS1PRSS2PRSS3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-0649425-B1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | UPJOHN CO (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5597816-A | Pyrazoloazepino substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1997-01-28 | — | — | US | disclosed |
| US-5565468-A | 4,5,6,7-TETRAHYDROPYRAZOLO(1,5-A)PYRID-3-YL, PYRAZOLO(1,5-A)PYRID-3-YL, IMIDAZO(1,5-A)PYRIDIN-1-YL OR IMIDAZO(1,2-A)-PYRID-3-YL OXIME DERIVATIVES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5523318-A | Pyrrolidino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0649425-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993025553-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | THE UPJOHN COMPANY (US) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | F2 791/4885PRSS1 1027/4885PRSS2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.